» Articles » PMID: 32846839

Persistent SARS-COV-2 RNA Positivity in a Patient for 92 Days After Disease Onset: A Case Report

Overview
Specialty General Medicine
Date 2020 Aug 28
PMID 32846839
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Recently, patients with COVID-19 who showed persistently positive SARS-CoV-2 nucleic acid test results despite resolved clinical symptoms have attracted a lot of attention. We report the case of a patient with mild symptoms of coronavirus disease (COVID-19), who achieved clinical recovery but showed persistently positive SARS-CoV-2 nucleic acid test results until Day 92 after disease onset.

Patient Concerns: The patient is a 50-year-old man with mild symptoms of coronavirus disease (COVID-19).

Diagnoses: COVID-19 pneumonia.

Interventions: The patient was quarantined for 105 days. Of these, inpatient quarantine lasted for 75 days. When the nucleic acid test results were negative for 3 consecutive days, the patient was discharged at Day 75 after disease onset. During this period, multiple samples were collected from the patient's body surface, the surrounding environment, and physical surfaces, but none of these tested positive for SARS-CoV-2. These samples included those from anal swabs, hands, inner surface of mask, cell phone, bed rails, floor around the bed, and toilet bowl surface. However, nucleic acid retest results on Day 80 and Day 92 after disease onset were positive for SARS-CoV-2 nucleic acids.

Outcomes: The patient continued with quarantine and observation at home. After the test results on Days 101 and 105 after disease onset were negative, quarantine was terminated at last.

Lessons: Per our knowledge, this is the longest known time that a patient has tested positive for SARS-CoV-2 nucleic acids. No symptoms were observed during follow-up. During hospitalization, the SARS-CoV-2 nucleic acid positivity was not observed in samples from the body surface and surrounding environment, and no verified transmission event occurred during the quarantine at home. After undergoing clinical recovery a minority of patients with COVID-19 have shown long-term positive results for the presence of the SARS-CoV-2 nucleic acid. This has provided new understanding and research directions for coronavirus infection. Long-term follow-up and quarantine measures have been employed for such patients. Further studies are required to analyze potential infectivity in such patients and determine whether more effective antiviral drugs or regimens to enable these patients to completely clear viral infection should be researched.

Citing Articles

Testing for SARS-CoV-2: lessons learned and current use cases.

Theel E, Kirby J, Pollock N Clin Microbiol Rev. 2024; 37(2):e0007223.

PMID: 38488364 PMC: 11237512. DOI: 10.1128/cmr.00072-23.


Long-term effects of SARS-CoV-2 infection on human brain and memory.

Ding Q, Zhao H Cell Death Discov. 2023; 9(1):196.

PMID: 37380640 PMC: 10307823. DOI: 10.1038/s41420-023-01512-z.


Determining SARS-CoV-2 non-infectivity state-A brief overview.

Brynjolfsson S, Sigurgrimsdottir H, Gudlaugsson O, Kristjansson M, Kristinsson K, Ludviksson B Front Public Health. 2022; 10:934242.

PMID: 36033758 PMC: 9412020. DOI: 10.3389/fpubh.2022.934242.


Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study.

Phuphuakrat A, Pasomsub E, Srichatrapimuk S, Kirdlarp S, Suksatu A, Srisaowakarn C Microbiol Spectr. 2022; 10(3):e0050322.

PMID: 35604133 PMC: 9241878. DOI: 10.1128/spectrum.00503-22.


Prolonged fecal shedding of SARS-CoV-2 in a young immunocompetent COVID-19 patient: A case report and literature overview.

Xiao F, Wan P, Wei Q, Wei G, Yu Y J Med Virol. 2022; 94(7):3133-3137.

PMID: 35274321 PMC: 9088484. DOI: 10.1002/jmv.27694.


References
1.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

2.
Xiao T, Wang Y, Yuan J, Ye H, Wei L, Liao X . Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers. Front Med (Lausanne). 2021; 8:595773. PMC: 8005564. DOI: 10.3389/fmed.2021.595773. View

3.
Yao X, He Z, Li T, Zhang H, Wang Y, Mou H . Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient. Cell Res. 2020; 30(6):541-543. PMC: 7186763. DOI: 10.1038/s41422-020-0318-5. View

4.
Gandhi M, Yokoe D, Havlir D . Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. N Engl J Med. 2020; 382(22):2158-2160. PMC: 7200054. DOI: 10.1056/NEJMe2009758. View

5.
Tan L, Kang X, Zhang B, Zheng S, Liu B, Yu T . Plasma therapy cured a COVID-19 patient with long duration of viral shedding for 49 days: The clinical features, laboratory tests, plasma therapy, and implications for public health management. MedComm (2020). 2021; 1(1):77-80. PMC: 7262084. DOI: 10.1002/mco2.2. View